Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings

The indications of immune checkpoint inhibitors (ICPIs) for cancer treatment have rapidly expanded, and their use is increasing in clinical settings worldwide. Despite the considerable clinical benefits of ICPIs, frequent immune-related adverse events (irAEs) have become nonnegligible concerns. Amon...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Tsutomu, Iijima, Hideki, Adachi, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751508/
https://www.ncbi.nlm.nih.gov/pubmed/31559106
http://dx.doi.org/10.4291/wjgp.v10.i2.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751508/
https://www.ncbi.nlm.nih.gov/pubmed/31559106
http://dx.doi.org/10.4291/wjgp.v10.i2.17

Ejemplares similares